H. Scheible

发表

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

A. Johne, H. Scheible, A. Becker, 2020, Investigational New Drugs.

A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance

W. Humphreys, R. Obach, C. Prakash, 2018, Drug Metabolism and Disposition.

Insights into Praziquantel metabolism and potential enantiomeric CYP-mediated drug-drug interaction.

H. Burt, P. Swart, H. Scheible, 2020, Drug metabolism and disposition: the biological fate of chemicals.

In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS

S. Laufer, M. Godejohann, C. Gleiter, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

A. Johne, H. Scheible, O. von Richter, 2016, British journal of clinical pharmacology.

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

A. Port, H. Scheible, J. V. van Lier, 2021, Clinical and translational science.

Metabolism and disposition of the αv‐integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

A. Kovar, A. Johne, H. Scheible, 2015, Journal of clinical pharmacology.

Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor

C. Gleiter, W. Albrecht, B. Kammerer, 2007, Drug Metabolism and Disposition.

In vitro and in vivo drug disposition of cilengitide in animals and human

T. Yamagata, H. Scheible, H. Dolgos, 2016, Pharmacology research & perspectives.

Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human

A. Javornik, H. Scheible, H. Dolgos, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors

F. Kraetzer, A. Johne, H. Scheible, 2017, Drug Metabolism and Disposition.

Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor

Stefan A. Laufer, C. Gleiter, W. Albrecht, 2007 .